Chemomab Therapeutics Ltd. (CMMB) › Cash & EquivalentsChemomab Therapeutics Ltd. (CMMB) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2018: $7.52M2019: $17.57M2020: $11.67M2021: $15.19M2022: $13.52M2023: $9.29M2024: $6.07M2025: $7.56M$7.56M2018Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$7.56M+24.6%2024$6.07M-34.7%2023$9.29M-31.3%2022$13.52M-11.0%2021$15.19M+30.1%2020$11.67M-33.6%2019$17.57M+133.8%2018$7.52M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share